Lung cancer is the major cause of cancer death worldwide. Cancer immunotherapy has been introduced as a promising and effective treatment that can improve the immune system’s ability to eliminate cancer cells and help establish immunological memory. Nanoparticles can contribute to the rapidly evolving field of immunotherapy by simultaneously delivering a variety of immunological agents to the target site and tumor microenvironment. Nano drug delivery systems can precisely target biological pathways and be implemented to reprogram or regulate immune responses. Numerous investigations have been conducted to employ different types of nanoparticles for immunotherapy of lung cancer. Nano-based immunotherapy adds a strong tool to the diverse collection of cancer therapies. This review briefly summarizes the remarkable potential opportunities for nanoparticles in lung cancer immunotherapy and its challenges.
Humankind’s quest to defeat cancer continues by developing targeted treatments. Among the frequently used cancer treatments with significant improvements are chemotherapy, radiation therapy, surgery, and combinations of them. However, these strategies have various limitations; for instance, although surgery offers the best outcome for cancers detected at early stages, this approach often falls short for cancers detected at late stages which have already spread throughout the body. Furthermore, chemotherapy has low specificity, drug-induced side effects, and drug resistance, and has shown higher cancer relapse rates similar to radiation therapy (Velpurisiva et al., 2017; Doroudian et al., 2020; Niloy et al., 2021; Anconina et al., 2022; Hosseinkazemi et al., 2022). As a result, researchers were encouraged to make use of the human body’s own defense system as a tool to fight cancer.